Press

IntelGenx Reports Third Quarter 2022 Financial Results

Nov 11 • 4 min read

IntelGenx Technologies Corp. (TSX:IGX | OTCQB:IGXT) today reported financial results for the third quarter ended September 30, 2022. All dollar amounts are expressed in U.S. currency, unless otherwise indicated, and results are reported in accordance with United States generally accepted accounting principles except where noted otherwise. 2022 Third Quarter Financial Summary: Revenue was $142,000, compared to $593,000 in the 2021…

Small Pharma to Participate in November Investor and Healthcare Conferences

Nov 11 • 2 min read

Small Pharma Inc. (TSXV: DMT | OTCQB: DMTTF) , a biotechnology company focused on short-acting psychedelic-assisted therapies for mental health conditions, is pleased to announce its participation in the following upcoming conferences in November. Jefferies London Healthcare Conference, November 15-17 George Tziras, Chief Executive Officer of the Company, will participate in a fireside chat on…

Silo Pharma Achieves New Milestone for SP-26 Therapeutic -Initiates IND Enabling Study of Topical Ketamine Formulation

Nov 11 • 2 min read

Silo Pharma, Inc. (Nasdaq: SILO), a developmental stage biopharmaceutical company focused on merging traditional therapeutics with psychedelic research, today announced initial dosing in its IND-enabling study of SP-26, its novel time-released, topical formulation of ketamine. The objective of this safety evaluation study, conducted by Experimur, a Frontage Company, is to evaluate the tolerability of the SP-26…

Relmada Therapeutics Provides Corporate Update and Reports Third Quarter 2022 Financial Results

Nov 11 • 4 min read

Relmada Therapeutics, Inc. (Nasdaq: RLMD), a late-stage biotechnology company addressing diseases of the central nervous system (CNS), today provided a corporate update and announced preliminary and unaudited financial results for the three and nine months ended September 30, 2022. The Company will host a conference call today, Thursday, November 10, at 4:30 PM Eastern Time/1:30 PM Pacific Time. “We…

Filament Health Announces Third Quarter 2022 Financial Results and Operational Highlights

Nov 10 • 3 min read

Filament Health Corp. (OTCQB: FLHLF | NEO: FH | FSE: 7QS), a clinical-stage natural psychedelic drug development company, released its second quarter financial results and operational highlights for the period ended September 30, 2022. “Our third quarter demonstrated Filament’s continued progress both internally and externally. The closure of a $2.5 million financing provided our drug development…

Pages: 123456789101112131415161718192021222324252627282930313233343536373839404142434445464748495051525354555657585960616263646566676869707172737475767778798081828384858687888990919293949596979899100101102103104105106107108109110111112113114115116117118119120121122123124125126127128129130131132133134135136137138139140141142143144145146147148149150151152153154155156157158159160161162163164165166167168169170171172173174175176177178179180181182183184185186187188189190191192193194195196197198199200201202203204205206207208209210211212213214215216217218219220221222223224225226227228229230231232233234235236237238239240241242243244245246247248249250251252253254255256257258259260261262263264265266267268269270271272273274275276277278279280281282283284285286287288289290291292293294295296297298299300301302303304305306307308309310311312313314315316317318319320321322323324325326327328329330331332333334335336337338339340341342343344345346347348349350351352353354355356357358359360361362363364365366367368369370371372373374375376377378379380381382383384385386387388389390391392393394395396397398399400401402403404405406407408409410411412413414415416417418419420421422423424425426427428429430431432433434435436437438439440441